Aardvark Therapeutics (AARD) is a pre-revenue clinical-stage biopharma with zero product revenue as of Q1 2026 (period ended March 31, 2026). Under a liquidation lens, recovery to equity is positive but thin relative to the book equity balance, driven almost entirely by cash and short-term investments. Total assets of $98.6M consist of $62.4M cash, $28.8M short-term investments (U.S. Treasury or similar high-grade securities all maturing within one year per XBRL disclosure), $2.4M prepaid/other current assets, $4.7M noncurrent assets (likely security deposit and ROU asset), and a de minimis PP&E base implied by $11K quarterly D&A. Applying standard liquidation haircuts: cash at 100% yields $62.4M; short-term investments at 100% (money market and short-duration IG fixed income) yield $28.8M; prepaid at 50% yields ~$1.2M; noncurrent assets (ROU $0.3M, other $4.7M) recoverable at roughly 0-20%, yielding ~$0.5M. Gross liquidation asset recovery approximates $92.9M. Total liabilities are $11.6M, all current, comprising accounts payable $4.5M, accrued liabilities $6.8M (of which employee-related $1.5M, other accrued $0.8M), and operating lease liability $0.3M. No long-term debt, no pension, no deferred revenue, no convertible notes. All liabilities stay at face value: $11.6M. Net liquidation recovery to equity approximates $81.3M versus XBRL-tagged book equity of $87.0M. The gap reflects haircuts on prepaid and noncurrent assets and is consistent with a liquid, cash-heavy, near-development-stage entity. The $137.5M accumulated deficit signals sustained cash burn; the company has disclosed approximately $65.3M of IPO proceeds consumed through March 31, 2026. Current quarter operating cash outflow was $18.9M, implying roughly 4-5 quarters of runway at current burn against the $91.2M combined cash and short-term investment balance. The February 2026 voluntary pause of Phase 3 HERO trial, OLE trial for ARD-101, and POWER/STRENGTH trials for ARD-201 due to reversible cardiac observations in a healthy volunteer study is a material clinical development setback disclosed in MD&A. This event does not alter balance-sheet liquidation math directly but accelerates the read-through: pipeline intangible value is zero in a liquidation, and a clinical hold increases the probability the company reaches a forced liquidity decision before generating revenue. The filing does not separately XBRL-tag clinical hold contingent liabilities or trial wind-down cost estimates. The $400M shelf registration (effective April 3, 2026) and $150M ATM facility (no sales as of March 31, 2026) are disclosed in narrative but not tagged in XBRL; these represent potential future claims dilution but no current balance-sheet liability.
▼ Community Notes